Transformation of the naturally occurring frog skin peptide, alyteserin-2a into a potent, non-toxic anti-cancer agent
Alyteserin-2a (ILGKLLSTAAGLLSNL.NH 2 ) is a cationic, amphipathic α-helical cell-penetrating peptide, first isolated from skin secretions of the midwife toad Alytes obstetricans . Structure–activity relationships were investigated by synthesizing analogs of alyteserin-2a in which amino acids on the...
Gespeichert in:
Veröffentlicht in: | Amino acids 2013-02, Vol.44 (2), p.715-723 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Alyteserin-2a (ILGKLLSTAAGLLSNL.NH
2
) is a cationic, amphipathic α-helical cell-penetrating peptide, first isolated from skin secretions of the midwife toad
Alytes obstetricans
. Structure–activity relationships were investigated by synthesizing analogs of alyteserin-2a in which amino acids on the hydrophobic face of the helix were replaced by
l
-tryptophan and amino acids on the hydrophilic face were replaced by one or more
l
-lysine or
d
-lysine residues. The Trp-containing peptides display increased cytotoxic activity against non-small cell lung adenocarcinoma A549 cells (up to 11-fold), but hemolytic activity against human erythrocytes increases in parallel. The potency of the N15K analog against A549 cells (LC
50
= 13 μM) increases sixfold relative to alyteserin-2a and the therapeutic index (ratio of LC
50
for erythrocytes and tumor cells) increases twofold. Incorporation of a
d
-Lys
11
residue into the N15K analog generates a peptide that retains potency against A549 cells (LC
50
= 15 μM) but whose therapeutic index is 13-fold elevated relative to the native peptide. [G11k, N15K] alyteserin-2a is also active against human hepatocarcinoma HepG2 cells (LC
50
= 26 μM), breast adenocarcinoma MDA-MB-231 cells (LC
50
= 20 μM), and colorectal adenocarcinoma HT-29 cells (LC
50
= 28 μM). [G11k, N15K] alyteserin-2a, in concentrations as low as 1 μg/mL, significantly (
P
|
---|---|
ISSN: | 0939-4451 1438-2199 |
DOI: | 10.1007/s00726-012-1395-7 |